Advertisement

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

      Abstract

      Background

      Poly(ADP-ribose) polymerase (PARP)-inhibitors and anti-angiogenics have activity in recurrent ovarian and breast cancer; however, the effect of combined therapy against PARP and angiogenesis in this population has not been reported. We investigated the toxicities and recommended phase 2 dosing (RP2D) of the combination of cediranib, a multitargeted inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3 and olaparib, a PARP-inhibitor (NCT01116648).

      Methods

      Cediranib tablets once daily and olaparib capsules twice daily were administered orally in a standard 3+3 dose escalation design. Patients with recurrent ovarian or metastatic triple-negative breast cancer were eligible. Patients had measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or met Gynecologic Cancer InterGroup (GCIG) CA125 criteria. No prior PARP-inhibitors or anti-angiogenics in the recurrent setting were allowed.

      Results

      28 patients (20 ovarian, 8 breast) enrolled to 4 dose levels. 2 dose limiting toxicities (DLTs) (1 grade 4 neutropenia ⩾4 days; 1 grade 4 thrombocytopenia) occurred at the highest dose level (cediranib 30 mg daily; olaparib 400 mg twice daily [BID]). The RP2D was cediranib 30 mg daily and olaparib 200 mg BID. Grade 3 or higher toxicities occurred in 75% of patients, and included grade 3 hypertension (25%) and grade 3 fatigue (18%). One grade 3 bowel obstruction occurred. The overall response rate (ORR) in the 18 RECIST-evaluable ovarian cancer patients was 44%, with a clinical benefit rate (ORR plus stable disease (SD) >24 weeks) of 61%. None of the seven evaluable breast cancer patients achieved clinical response; two patients had stable disease for >24 weeks.

      Interpretation

      The combination of cediranib and olaparib has haematologic DLTs and anticipated class toxicities, with promising evidence of activity in ovarian cancer patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ame J.C.
        • Spenlehauer C.
        • de Murcia G.
        The PARP superfamily.
        Bioessays. 2004; 26: 882-893
        • Ashworth A.
        A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
        J Clin Oncol. 2008; 26: 3785-3790
        • McCabe N.
        • Turner N.C.
        • Lord C.J.
        • et al.
        Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
        Cancer Res. 2006; 66: 8109-8115
        • Bryant H.E.
        • Schultz N.
        • Thomas H.D.
        • et al.
        Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
        Nature. 2005; 434: 913-917
        • Farmer H.
        • McCabe N.
        • Lord C.J.
        • et al.
        Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
        Nature. 2005; 434: 917-921
        • Audeh M.W.
        • Carmichael J.
        • Penson R.T.
        • et al.
        Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
        Lancet. 2010; 376: 245-251
        • Tutt A.
        • Robson M.
        • Garber J.E.
        • et al.
        Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
        Lancet. 2010; 376: 235-244
        • Gelmon K.A.
        • Tischkowitz M.
        • Mackay H.
        • et al.
        Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
        Lancet Oncol. 2011; 12: 852-861
        • Balmana J.
        • Tung N.M.
        • Isakoff S.J.
        • et al.
        Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.
        J Clin Oncol. 2012; ([abstr. 1009])
        • Rajan A.
        • Carter C.A.
        • Kelly R.J.
        • et al.
        A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
        Clin Cancer Res. 2012; 18: 2344-2351
        • Dean E.
        • Middleton M.R.
        • Pwint T.
        • et al.
        Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
        Br J Cancer. 2012; 106: 468-474
        • Burger R.A.
        • Sill M.W.
        • Monk B.J.
        • Greer B.E.
        • Sorosky J.I.
        Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
        J Clin Oncol. 2007; 25: 5165-5171
        • Cannistra S.A.
        • Matulonis U.A.
        • Penson R.T.
        • et al.
        Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
        J Clin Oncol. 2007; 25: 5180-5186
        • Matulonis U.A.
        • Berlin S.
        • Ivy P.
        • et al.
        Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
        J Clin Oncol. 2009; 27: 5601-5606
        • Miller K.
        • Wang M.
        • Gralow J.
        • et al.
        Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
        New Engl J Med. 2007; 357: 2666-2676
        • Mayer E.L.
        • Hamell S.
        • Savoie J.
        • et al.
        AZD2171 for refractory breast cancer: a phase 2 trial.
        Breast Cancer Res Treat. 2007; 106 ([abstr. 6080]): S274
        • Tentori L.
        • Lacal P.M.
        • Muzi A.
        • et al.
        Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.
        Eur J Cancer. 2007; 43: 2124-2133
        • Bindra R.S.
        • Gibson S.L.
        • Meng A.
        • et al.
        Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.
        Cancer Res. 2005; 65: 11597-11604
        • Bindra R.S.
        • Schaffer P.J.
        • Meng A.
        • et al.
        Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells.
        Mol Cell Biol. 2004; 24: 8504-8518
        • Chan N.
        • Bristow R.G.
        “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair.
        Clin Cancer Res. 2010; 16: 4553-4560
        • Hegan D.C.
        • Lu Y.
        • Stachelek G.C.
        • et al.
        Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.
        Proc Natl Acad Sci U S A. 2010; 107: 2201-2206
        • Rustin G.J.
        Use of CA-125 to assess response to new agents in ovarian cancer trials.
        J Clin Oncol. 2003; 21: 187s-193s
        • Fong P.C.
        • Boss D.S.
        • Yap T.A.
        • et al.
        Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
        N Engl J Med. 2009; 361: 123-134